title: Prostaglandin I2 analog suppresses lung metastasis by recruiting pericytes in tumor angiogenesis.
abstract: Prostaglandin I2 (PGI2) agonist has been reported to reduce tumor metastasis by modifying tumor angiogenesis; however, the mechanisms of how PGI2 affects the endothelial cells or pericytes in tumor vessel maturation are still unclear. The purpose of this study was to clarify the effects of PGI2 on tumor metastasis in a mouse lung metastasis model using Lewis lung carcinoma (LLC) cells. The mice were treated continuously with beraprost sodium (BPS), a PGI2 analog, for 3 weeks and then examined for lung metastases. The number and size of lung metastases were decreased significantly by BPS treatment. In addition, scanning electron microscopy and immunohistochemistry revealed that BPS increased the number of tumor‑associated pericytes and improved intratumor hypoxia. Collectively, this study suggests that BPS attenuated vascular functional maturation in metastatic tumors.
authors.affiliation: Respiratory Center, Asahikawa Medical University, Asahikawa, Hokkaido 078‑8510, Japan.
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Minami
authors.affiliation: Respiratory Center, Asahikawa Medical University, Asahikawa, Hokkaido 078‑8510, Japan.
authors.forename: Takaaki
authors.initials: T
authors.lastname: Sasaki
authors.affiliation: Department of Microscopic Anatomy and Cell Biology, Asahikawa Medical University, Asahikawa, Hokkaido 078‑8510, Japan.
authors.forename: Hiroki
authors.initials: H
authors.lastname: Bochimoto
authors.affiliation: Department of Cardiovascular Regeneration and Innovation, Asahikawa Medical University, Asahikawa, Hokkaido 078‑8510, Japan.
authors.forename: Jun-Ichi
authors.initials: J
authors.lastname: Kawabe
authors.affiliation: Respiratory Center, Asahikawa Medical University, Asahikawa, Hokkaido 078‑8510, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Endo
authors.affiliation: Department of Microscopic Anatomy and Cell Biology, Asahikawa Medical University, Asahikawa, Hokkaido 078‑8510, Japan.
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Hira
authors.affiliation: Department of Microscopic Anatomy and Cell Biology, Asahikawa Medical University, Asahikawa, Hokkaido 078‑8510, Japan.
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Watanabe
authors.affiliation: Respiratory Center, Asahikawa Medical University, Asahikawa, Hokkaido 078‑8510, Japan.
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Okumura
authors.affiliation: Cardiovascular, Respiratory and Neurology Division, Department of Medicine, Asahikawa Medical University, Asahikawa, Hokkaido 078‑8510, Japan.
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Hasebe
authors.affiliation: Respiratory Center, Asahikawa Medical University, Asahikawa, Hokkaido 078‑8510, Japan.
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Ohsaki
mesh_terms: D000818:Animals; D001808:Blood Vessels / Q000187:drug effects / Q000473:pathology; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D011464:Epoprostenol / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D051379:Mice; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D020286:Pericytes / Q000187:drug effects
chemical_list: C048081:beraprost; D011464:Epoprostenol